Madrigal Pharmaceuticals (NASDAQ:MDGL) traded ~10% higher on Tuesday after the Pennsylvania-based biotech posted a strong quarterly beat with its Q2 2025 results, thanks mainly to increased uptake for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results